These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 21749884)

  • 1. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
    Ky B; Carver JR
    Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A historical perspective of anthracycline cardiotoxicity.
    Ewer MS; Von Hoff DD; Benjamin RS
    Heart Fail Clin; 2011 Jul; 7(3):363-72. PubMed ID: 21749888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Promote multidisciplinary study on anthracycline-induced cardiotoxicity in children].
    Chen SB; Huang MR; Tang JY
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):565-8. PubMed ID: 24225284
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
    Appel JM; Rybjerg M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
    [No Abstract]   [Full Text] [Related]  

  • 15. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
    Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
    Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.
    Mavinkurve-Groothuis AM; Kapusta L; Nir A; Groot-Loonen J
    Pediatr Hematol Oncol; 2008 Sep; 25(7):655-64. PubMed ID: 18850478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
    Johnson SA
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S22-7. PubMed ID: 16781286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of antracycline toxicity: modern approaches to diagnosis, prevention, and treatment].
    Fandeev OA; Vasechkin SS; Alekhin MN; Odintsov SV; Kallistov VE; Sidorenko BA
    Kardiologiia; 2011; 51(7):40-6. PubMed ID: 21878084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Levis BE; Binkley PF; Shapiro CL
    Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.